#Ticagrelor Added to #Aspirin in Acute Ischemic #Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke A Randomized Clinical Trial

Reduction of subsequent disabling stroke is the main goal of preventive treatment in the acute setting after transient ischemic attack (TIA) or minor ischemic stroke.. ..Ticagrelor (180-mg loading dose on day 1 followed by 90 mg twice daily for days 2-30) or placebo within 24 hours of symptom onset. All patients received aspirin, 300 to 325 mg on day 1 followed by 75 to 100 … Continue reading #Ticagrelor Added to #Aspirin in Acute Ischemic #Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke A Randomized Clinical Trial

#ASPIRIN AND THE RISK OF NON‐DIGESTIVE TRACT CANCERS: AN UPDATED META‐ANALYSIS TO 2019

Aspirin has been associated to a reduced risk of colorectal and other selected digestive tract cancers, but the evidence other neoplasms is still controversial. In order to provide an up‐to‐date quantification of the role of aspirin on lung, breast, endometrium, ovary, prostate, bladder, and kidney cancer, we conducted a systematic review and meta‐analysis of all observational studies published up to March 2019. We estimated pooled … Continue reading #ASPIRIN AND THE RISK OF NON‐DIGESTIVE TRACT CANCERS: AN UPDATED META‐ANALYSIS TO 2019

#Aspirin use and risk of #breast cancer in African American women

Use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been hypothesized to be associated with reduced risk of breast cancer; however, results of epidemiological studies have been mixed. Few studies have investigated these associations among African American women.. To assess the relation of aspirin use to risk of breast cancer in African American women, we conducted a prospective analysis within the Black Women’s Health … Continue reading #Aspirin use and risk of #breast cancer in African American women

#Aspirin with or without #Clopidogrel after Transcatheter Aortic- #Valve Implantation

The effect of single as compared with dual antiplatelet treatment on bleeding and thromboembolic events after transcatheter aortic-valve implantation (TAVI) in patients who do not have an indication for long-term anticoagulation has not been well studied.. ..A total of 331 patients were assigned to receive aspirin alone and 334 were assigned to receive aspirin plus clopidogrel. A bleeding event occurred in 50 patients (15.1%) receiving … Continue reading #Aspirin with or without #Clopidogrel after Transcatheter Aortic- #Valve Implantation

#Coronary Artery Calcium for Personalized Allocation of #Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The Multi-Ethnic Study of Atherosclerosis (MESA)

..The present study aimed to assess the value of coronary artery calcium (CAC) for guiding aspirin allocation for primary prevention using 2019 aspirin meta-analysis data on CVD relative risk reduction (RRR) and bleeding risk ..Only 5% of MESA participants would qualify for aspirin consideration for primary prevention according to ACC/AHA guidelines and using >20% estimated ASCVD risk to define “higher risk”. Benefit/harm calculations were restricted … Continue reading #Coronary Artery Calcium for Personalized Allocation of #Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The Multi-Ethnic Study of Atherosclerosis (MESA)

#Aspirin for primary prevention of cardiovascular disease, part 2

..ASPREE study suggests no benefit from aspirin in primary prevention ASPREE randomized 19,114 healthy people 70 or over (65 or over for African Americans and Hispanics) to receive either 100 milligrams of enteric-coated aspirin or placebo. After an average of almost five years, there was no significant difference in the rate of fatal coronary heart disease, heart attack, stroke, or hospitalization for heart failure. There … Continue reading #Aspirin for primary prevention of cardiovascular disease, part 2

Clinical Influence of Nonadherence With Prophylactic #Aspirin in Preventing #Preeclampsia in High-Risk Pregnancies

..Women with inadequate adherence had higher incidence of early-onset preeclampsia (17% versus 2%; odds ratio [OR], 1.9 [95% CI, 1.1–8.7]; P=0.04), late-onset preeclampsia (41% versus 5%; OR, 4.2 [95% CI, 1.4–19.8]; P=0.04), intrauterine growth restriction (29% versus 5%; OR, 5.8; [95% CI, 1.2–8.3]; P=0.001), preterm delivery (27% versus 10%; OR, 5.2 [95% CI, 1.5–8.7]; P=0.008), and higher likelihood of increase in antihypertensives antenatally (60% versus … Continue reading Clinical Influence of Nonadherence With Prophylactic #Aspirin in Preventing #Preeclampsia in High-Risk Pregnancies

Clinical Effectiveness and Safety of #Aspirin for Venous #Thromboembolism Prophylaxis After Total Hip and Knee Replacement

Patients undergoing total hip replacement (THR) and total knee replacement (TKR) receive venous thromboembolism (VTE) pharmacoprophylaxis. It is unclear which anticoagulant is preferable. Observational data suggest aspirin provides effective VTE prophylaxis.. ..The RR of VTE after THR and TKR was 1.12 (95% CI, 0.78-1.62) for aspirin compared with other anticoagulants. Comparable findings were observed for deep vein thrombosis (DVT) (RR, 1.04; 95% CI, 0.72-1.51) and … Continue reading Clinical Effectiveness and Safety of #Aspirin for Venous #Thromboembolism Prophylaxis After Total Hip and Knee Replacement

#Aspirin and #fracture risk: a systematic review and exploratory meta-analysis of observational studies

This review provides insights into the potential for aspirin to preserve bone mineral density (BMD) and reduce fracture risk, building knowledge of the risk-benefit profile of aspirin. ..Aspirin use was associated with a 17% lower odds for any fracture (OR 0.83, 95% CI 0.70 to 0.99; I2=71%; six studies; n=511 390). Aspirin was associated with a higher total hip BMD for women (SMD 0.03, 95% CI −0.02 to … Continue reading #Aspirin and #fracture risk: a systematic review and exploratory meta-analysis of observational studies

Low‐Dose #Aspirin for Primary Prevention of #Cardiovascular Disease: Use Patterns and Impact Across Race and Ethnicity in the Southern Community Cohort Study

..Over a median follow‐up of 11.3 years, low‐dose aspirin use was associated with a trend toward decreased risk of ischemic cardiac death in white participants (adjusted hazard ratio: 0.86; 95% CI, 0.68–1.10), especially in women (adjusted hazard ratio: 0.72; 95% CI, 0.51–1.02), but not in black participants (adjusted hazard ratio: 1.18; 95% CI, 0.98–1.40). Similar trends were observed when the analysis was restricted to high‐risk … Continue reading Low‐Dose #Aspirin for Primary Prevention of #Cardiovascular Disease: Use Patterns and Impact Across Race and Ethnicity in the Southern Community Cohort Study

#Aspirin for primary #prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups

..major adverse cardiovascular events (MACE) ..Aspirin use did not translate into a net clinical benefit adjusted for event-associated mortality risk (mean 0.034%; 95% CI, − 0.18 to 0.25%). There was an interaction for aspirin effect in three patient subgroups: (i) in patients under statin treatment, aspirin was associated with a 12% RRR of MACE (RR 0.88; 95% CI, 0.80–0.96), and this effect was lacking in the … Continue reading #Aspirin for primary #prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups

Ticagrelor with or without Aspirin in High-Risk Patients after PCI

Monotherapy with a P2Y12 inhibitor after a minimum period of dual antiplatelet therapy is an emerging approach to reduce the risk of bleeding after percutaneous coronary intervention (PCI). ..The difference in risk between the groups was similar for BARC type 3 or 5 bleeding (incidence, 1.0% among patients receiving ticagrelor plus placebo and 2.0% among patients receiving ticagrelor plus aspirin; hazard ratio, 0.49; 95% CI, … Continue reading Ticagrelor with or without Aspirin in High-Risk Patients after PCI